NYKD: Nykode Therapeutics to Present and Participate in Fireside Chat at the 17th DNB Carnegie Nordic Healthcare Conference
2026-11-20 12:00:00
Oslo, Norway, November 20, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of cancer vaccines, today announced that its CEO, Michael Engsig,
and Chief Scientific Officer and Co-founder, Agnete Fredriksen, will participate
in the 17th DNB Carnegie Nordic Healthcare Conference on Tuesday, November 24,
2026, in Oslo, Norway. The company's participation will include a company
presentation and fireside chat.
Presentation Details
Presenter: Michael Engsig & Agnete Fredriksen
Date: Tuesday, November 24, 2026
Time: 2:45-3:05 p.m. CET
Location: Auditorium 3
The presentation and fireside chat will provide an opportunity to discuss
Nykode's recent progress and key developments across its pipeline, including
abi-suva, its lead program in the Phase 2 Abili-T trial, and VB10.NEO, its
individualized neoantigen cancer vaccine, as well as the company's immune
tolerance platform.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.
Nykode's lead product candidate is abi-suva, a cancer vaccine for the treatment
of HPV16 induced malignancies which demonstrated favorable safety and efficacy
results from its Phase 2 trial for the treatment of late-line r/m cervical
cancer. Abi-suva is currently being further developed in first line head and
neck cancer with the randomized Abili-T trial with interim results within 2027.
VB10.NEO, an individualized cancer vaccine, has been investigated in two trials
with more than 10 different indications.
Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.
Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.
Contact for Nykode Therapeutics ASA:
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
.com\
\
Nykode Therapeutics ASA\
Oslo Science Park\
Gaustadalléen 21\
N-0349 Oslo\, Norway\